> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# AbbVie Cuts Full-Year Profit Guidance To $13.76-$13.96 A Share After $216 Million Research Charge
- URL: https://www.bullished.co/abbvie-cuts-full-year-profit-guidance-to-13-76-13-96-a-share-after-216-million-research-14477261/
- Published: 2026-10-05T20:25:55.000Z
- Updated: 2026-10-05T20:25:55.000Z
- Description: An 8-K puts a $0.11-per-share hit in the third quarter and lowers both the quarterly and full-year adjusted earnings ranges.
- Author: Matteo Parrino
- Tags: Earnings, ABBV, Industry: Healthcare

AbbVie lowered its 2026 adjusted earnings forecast to [$13.76 to $13.96 a share](https://www.sec.gov/Archives/edgar/data/0001551152/000155115226000030/abbv-20261005.htm?ref=bullished.co), from $13.87 to $14.07, after booking a preliminary $216 million research charge in the third quarter. The company disclosed the change in an 8-K filed Monday.

## What the 8-K says

The charge is acquired in-process research and development and milestones expense, the cost of buying or licensing outside drug research. It is pre-tax and unaudited, and it cuts both standard-accounting and adjusted earnings by $0.11 per share, according to the filing.

For the third quarter, AbbVie now guides to adjusted earnings of $3.73 to $3.77 per share, versus the $3.84 to $3.88 it gave before.

The full-year forecast now carries [$1,251 million](https://www.sec.gov/Archives/edgar/data/0001551152/000155115226000030/abbv-20260930nonxgaapxex991.htm?ref=bullished.co) of acquired research and milestones expense, up from $1,035 million. The $216 million accounts for the difference.

## Why the forecast moved

AbbVie does not forecast this kind of expense. The filing says the reason is uncertainty over whether and when such deals, including collaborations, licensing agreements and other asset purchases, will occur.

The July 31 guidance excluded the expense for any period beyond the second quarter of 2026\. Now that the third-quarter charge has been incurred, it flows into the numbers.

The exhibit adds that the 2026 range still excludes any such expense incurred beyond the third quarter, because it cannot be reliably forecast. A new deal in the fourth quarter would therefore change the reported figure again.

## What holders should note

The figures are preliminary. AbbVie said results for the quarter ended September 30, 2026 have not been finalized and are subject to its financial statement closing procedures. It also said there is no assurance the final results will not differ from these estimates.

The 8-K was signed by Scott T. Reents, AbbVie's executive vice president and chief financial officer. In Monday trading, as of 4:16 p.m. ET, the shares were at $265.76, up 1.12% (market data).

AbbVie's final third-quarter results, once its closing procedures finish, may differ from the $3.73 to $3.77 range in this filing.

### Sources

- [8-K Filing — AbbVie Inc. (ABBV)](https://www.sec.gov/Archives/edgar/data/0001551152/000155115226000030/abbv-20261005.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit abbv-20260930nonxgaapxex991.htm — AbbVie Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001551152/000155115226000030/abbv-20260930nonxgaapxex991.htm?ref=bullished.co) — SEC EDGAR